A study shows expanding access to care through insurance has the potential to improve outcomes in adults with follicular lymphoma.
How much do you know about the clinical course and genomics of follicular lymphoma? Take our latest quiz to find out.
Balancing the goal of obtaining a durable remission and that of avoiding a negative impact on quality of life argues against the routine use of chemotherapy in follicular lymphoma.
It is clear that chemoimmunotherapy has redefined the history of follicular lymphoma, producing survival rates measured in decades.
DLBCL and FL patients experience considerable economic burden during the first year after diagnosis.
The combination of obinutuzumab and lenalidomide was found to be effective in relapsed or refractory follicular B-cell lymphoma.
TROG 99.03 constitutes “the only high level evidence currently available to guide decision making for this group of patients,” says investigator Michael MacManus.
In addition to significant improvements in 5-year OS and PFS with maintenance rituximab, there was a trend toward an association between maintenance and reduced transformation risk.
AEs were more common in patients assigned to obinutuzumab compared with rituximab; however, baseline characteristics differed between treatment arms.
In the DAWN trial, however, investigators said, “some patients experienced prolonged remission durations and symptom relief with no new safety signals.”